{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:19:57Z","timestamp":1791688797282,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["F30AI74785"],"award-info":[{"award-number":["F30AI74785"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI128949"],"award-info":[{"award-number":["U19AI128949"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI128949"],"award-info":[{"award-number":["U19AI128949"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI128949"],"award-info":[{"award-number":["U19AI128949"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["TA-2204-39428"],"award-info":[{"award-number":["TA-2204-39428"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["COMB157GUS20T"],"award-info":[{"award-number":["COMB157GUS20T"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["COMB157GUS20T"],"award-info":[{"award-number":["COMB157GUS20T"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01151-8","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T03:10:23Z","timestamp":1747451423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapy"],"prefix":"10.1038","volume":"10","author":[{"given":"Julia","family":"Davis-Porada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceren","family":"Tozlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sokratis A.","family":"Apostolidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Bar-Or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley","family":"Bove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego A.","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugeidy","family":"Ferreira Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir","family":"Kakara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaho","family":"Onomichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelle","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Joseph J.","family":"Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. John","family":"Wherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongqi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"De Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Flanagan","family":"Wesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Straus Farber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna L.","family":"Farber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"1151_CR1","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccin. Immunol. 17, 1055\u20131065 (2010).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1151_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1081107","volume":"13","author":"SA Plotkin","year":"2022","unstructured":"Plotkin, S. A. Recent updates on correlates of vaccine-induced protection. Front. Immunol. 13, 1081107 (2022).","journal-title":"Front. Immunol."},{"key":"1151_CR3","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMp2211314","volume":"387","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. A covid-19 milestone attained\u2014a correlate of protection for vaccines. N. Engl. J. Med. 387, 2203\u20132206 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1151_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.13091","volume":"310","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 310, 6\u201326 (2022).","journal-title":"Immunol. Rev."},{"key":"1151_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114228","volume":"385","author":"Y Goldberg","year":"2021","unstructured":"Goldberg, Y. et al. Waning Immunity after the BNT162b2 Vaccine in Israel. N. Engl. J. Med. 385, e85 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1151_CR6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114583","volume":"385","author":"EG Levin","year":"2021","unstructured":"Levin, E. G. et al. Waning immune humoral response to bnt162b2 covid-19 vaccine over 6 months. N. Engl. J. Med. 385, e84 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1151_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28527-x","volume":"13","author":"H Ward","year":"2022","unstructured":"Ward, H. et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat. Commun. 13, 907 (2022).","journal-title":"Nat. Commun."},{"key":"1151_CR8","unstructured":"Goel, R. R. et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, eabm0829, (2021)."},{"key":"1151_CR9","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","volume":"185","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell 185, 2434\u20132451.e2417 (2022).","journal-title":"Cell"},{"key":"1151_CR10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaneurol.2023.1135","volume":"80","author":"M Hittle","year":"2023","unstructured":"Hittle, M. et al. Population-based estimates for the prevalence of multiple sclerosis in the united states by race, ethnicity, age, sex, and geographic region. JAMA Neurol. 80, 693\u2013701 (2023).","journal-title":"JAMA Neurol."},{"key":"1151_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1212\/WNL.0000000000007044","volume":"92","author":"LM Nelson","year":"2019","unstructured":"Nelson, L. M. et al. A new way to estimate neurologic disease prevalence in the United States: illustrated with MS. Neurology 92, 469\u2013480 (2019).","journal-title":"Neurology"},{"key":"1151_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1309\/UXLE9RHL968TER7B","volume":"130","author":"AM Cioc","year":"2008","unstructured":"Cioc, A. M. et al. Rituximab-induced changes in hematolymphoid tissues found at autopsy. Am. J. Clin. Pathol. 130, 604\u2013612 (2008).","journal-title":"Am. J. Clin. Pathol."},{"key":"1151_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff, M. E. et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435\u2013445 (1994).","journal-title":"Blood"},{"key":"1151_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1182\/blood.V69.2.584.584","volume":"69","author":"OW Press","year":"1987","unstructured":"Press, O. W. et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69, 584\u2013591 (1987).","journal-title":"Blood"},{"key":"1151_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser, S. L. et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 376, 221\u2013234 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1151_CR16","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser, S. L. et al. Ofatumumab versus teriflunomide in multiple sclerosis. N. Engl. J. Med. 383, 546\u2013557 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1151_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy356","volume":"6","author":"MR Ciardi","year":"2019","unstructured":"Ciardi, M. R. et al. Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis. Open Forum Infect. Dis. 6, ofy356 (2019).","journal-title":"Open Forum Infect. Dis."},{"key":"1151_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna, G. et al. Infection Risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 77, 184\u2013191 (2020).","journal-title":"JAMA Neurol."},{"key":"1151_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105387","volume":"82","author":"L Levine","year":"2024","unstructured":"Levine, L. et al. Inflammatory vaginitis in four B-cell suppressed women with multiple sclerosis. Mult. Scler. Relat. Disord. 82, 105387 (2024).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1151_CR20","doi-asserted-by":"publisher","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","volume":"95","author":"A Bar-Or","year":"2020","unstructured":"Bar-Or, A. et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology 95, e1999\u2013e2008 (2020).","journal-title":"Neurology"},{"key":"1151_CR21","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","volume":"27","author":"SA Apostolidis","year":"2021","unstructured":"Apostolidis, S. A. et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat. Med. 27, 1990\u20132001 (2021).","journal-title":"Nat. Med."},{"key":"1151_CR22","doi-asserted-by":"crossref","unstructured":"Sabatino, J. J., Jr. et al. Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function. JCI Insight 7, e156978 (2022).","DOI":"10.1172\/jci.insight.156978"},{"key":"1151_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.926318","volume":"13","author":"R Alfonso-Dunn","year":"2022","unstructured":"Alfonso-Dunn, R. et al. Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies. Front. Immunol. 13, 926318 (2022).","journal-title":"Front. Immunol."},{"key":"1151_CR24","doi-asserted-by":"crossref","unstructured":"Asashima, H. et al. Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination. JCI Insight 8, e168102 (2023).","DOI":"10.1172\/jci.insight.168102"},{"key":"1151_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103636","volume":"73","author":"SP Gadani","year":"2021","unstructured":"Gadani, S. P. et al. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. EBioMedicine 73, 103636 (2021).","journal-title":"EBioMedicine"},{"key":"1151_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1149629","volume":"14","author":"P Nytrova","year":"2023","unstructured":"Nytrova, P. et al. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab. Front. Immunol. 14, 1149629 (2023).","journal-title":"Front. Immunol."},{"key":"1151_CR27","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.4049\/jimmunol.2101142","volume":"208","author":"Y Yuzefpolskiy","year":"2022","unstructured":"Yuzefpolskiy, Y. et al. Cutting edge: effect of disease-modifying therapies on SARS-CoV-2 vaccine-induced immune responses in multiple sclerosis patients. J. Immunol. 208, 1519\u20131524 (2022).","journal-title":"J. Immunol."},{"key":"1151_CR28","doi-asserted-by":"publisher","first-page":"eadh4529","DOI":"10.1126\/scitranslmed.adh4529","volume":"15","author":"R Zonozi","year":"2023","unstructured":"Zonozi, R. et al. T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19. Sci. Transl. Med. 15, eadh4529 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1151_CR29","doi-asserted-by":"publisher","first-page":"103581","DOI":"10.1016\/j.ebiom.2021.103581","volume":"72","author":"MP Sormani","year":"2021","unstructured":"Sormani, M. P. et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine 72, 103581 (2021).","journal-title":"EBioMedicine"},{"key":"1151_CR30","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"130","author":"G Chen","year":"2020","unstructured":"Chen, G. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Investig. 130, 2620\u20132629 (2020).","journal-title":"J. Clin. Investig."},{"key":"1151_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or Mild COVID-19. Cell 183, 158\u2013168.e114 (2020).","journal-title":"Cell"},{"key":"1151_CR32","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.immuni.2021.03.005","volume":"54","author":"PA Szabo","year":"2021","unstructured":"Szabo, P. A. et al. Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. Immunity 54, 797\u2013814.e796 (2021).","journal-title":"Immunity"},{"key":"1151_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cca.2020.05.019","volume":"508","author":"R Liu","year":"2020","unstructured":"Liu, R. et al. Decreased T cell populations contribute to the increased severity of COVID-19. Clin. Chim. Acta 508, 110\u2013114 (2020).","journal-title":"Clin. Chim. Acta"},{"key":"1151_CR34","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser, S. L. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676\u2013688 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1151_CR35","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/acn3.51314","volume":"8","author":"SN Levin","year":"2021","unstructured":"Levin, S. N. et al. Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases. Ann. Clin. Transl. Neurol. 8, 918\u2013928 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1151_CR36","doi-asserted-by":"publisher","first-page":"e0186998","DOI":"10.1371\/journal.pone.0186998","volume":"12","author":"S Reiss","year":"2017","unstructured":"Reiss, S. et al. Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells. PLoS One 12, e0186998 (2017).","journal-title":"PLoS One"},{"key":"1151_CR37","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell 181, 1489\u20131501.e1415 (2020).","journal-title":"Cell"},{"key":"1151_CR38","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-031210-101400","volume":"29","author":"S Crotty","year":"2011","unstructured":"Crotty, S. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29, 621\u2013663 (2011).","journal-title":"Annu. Rev. Immunol."},{"key":"1151_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fimmu.2015.00016","volume":"6","author":"JS Hale","year":"2015","unstructured":"Hale, J. S. & Ahmed, R. Memory T follicular helper CD4 T cells. Front. Immunol. 6, 16 (2015).","journal-title":"Front. Immunol."},{"key":"1151_CR40","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1016\/j.immuni.2024.10.003","volume":"57","author":"J Davis-Porada","year":"2024","unstructured":"Davis-Porada, J. et al. Maintenance and functional regulation of immune memory to COVID-19 vaccines in tissues. Immunity 57, 2895\u20132913.e2898 (2024).","journal-title":"Immunity"},{"key":"1151_CR41","doi-asserted-by":"publisher","first-page":"577676","DOI":"10.1016\/j.jneuroim.2021.577676","volume":"359","author":"AE Lovett-Racke","year":"2021","unstructured":"Lovett-Racke, A. E. et al. B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report. J. Neuroimmunol. 359, 577676 (2021).","journal-title":"J. Neuroimmunol."},{"key":"1151_CR42","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1084\/jem.182.4.915","volume":"182","author":"MM Epstein","year":"1995","unstructured":"Epstein, M. M., Di Rosa, F., Jankovic, D., Sher, A. & Matzinger, P. Successful T cell priming in B cell-deficient mice. J. Exp. Med. 182, 915\u2013922 (1995).","journal-title":"J. Exp. Med."},{"key":"1151_CR43","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.4049\/jimmunol.1301284","volume":"192","author":"LG Barnett","year":"2014","unstructured":"Barnett, L. G. et al. B cell antigen presentation in the initiation of follicular helper T cell and germinal center differentiation. J. Immunol. 192, 3607\u20133617 (2014).","journal-title":"J. Immunol."},{"key":"1151_CR44","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.immuni.2010.07.015","volume":"33","author":"EK Deenick","year":"2010","unstructured":"Deenick, E. K. et al. Follicular helper T cell differentiation requires continuous antigen presentation that is independent of unique B cell signaling. Immunity 33, 241\u2013253 (2010).","journal-title":"Immunity"},{"key":"1151_CR45","first-page":"51","volume":"3","author":"TS Lin","year":"2010","unstructured":"Lin, T. S. Ofatumumab: a novel monoclonal anti-CD20 antibody. Pharmgenom. Pers. Med. 3, 51\u201359 (2010).","journal-title":"Pharmgenom. Pers. Med."},{"key":"1151_CR46","doi-asserted-by":"publisher","first-page":"e1805","DOI":"10.1212\/WNL.0000000000005516","volume":"90","author":"A Bar-Or","year":"2018","unstructured":"Bar-Or, A. et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. Neurology 90, e1805\u2013e1814 (2018).","journal-title":"Neurology"},{"key":"1151_CR47","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1002\/art.23732","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese, M. C. et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I\/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 58, 2652\u20132661 (2008).","journal-title":"Arthritis Rheum."},{"key":"1151_CR48","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1172\/JCI125740","volume":"129","author":"L Kahari","year":"2019","unstructured":"Kahari, L. et al. Transcytosis route mediates rapid delivery of intact antibodies to draining lymph nodes. J. Clin. Investig. 129, 3086\u20133102 (2019).","journal-title":"J. Clin. Investig."},{"key":"1151_CR49","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3389\/fimmu.2019.01340","volume":"10","author":"D Theil","year":"2019","unstructured":"Theil, D. et al. Imaging mass cytometry and single-cell genomics reveal differential depletion and repletion of B-cell populations following ofatumumab treatment in cynomolgus monkeys. Front. Immunol. 10, 1340 (2019).","journal-title":"Front. Immunol."},{"key":"1151_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.110071","volume":"37","author":"MML Poon","year":"2021","unstructured":"Poon, M. M. L. et al. Heterogeneity of human anti-viral immunity shaped by virus, tissue, age, and sex. Cell Rep. 37, 110071 (2021).","journal-title":"Cell Rep."},{"key":"1151_CR51","doi-asserted-by":"crossref","unstructured":"Szabo, P. A., Miron, M. & Farber, D. L. Location, location, location: Tissue resident memory T cells in mice and humans. Sci Immunol 4, eaas9673 (2019).","DOI":"10.1126\/sciimmunol.aas9673"},{"key":"1151_CR52","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41590-024-01787-z","volume":"25","author":"V Fumagalli","year":"2024","unstructured":"Fumagalli, V. et al. Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination. Nat. Immunol. 25, 633\u2013643 (2024).","journal-title":"Nat. Immunol."},{"key":"1151_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl4509","volume":"6","author":"B Israelow","year":"2021","unstructured":"Israelow, B. et al. Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Sci. Immunol. 6, eabl4509 (2021).","journal-title":"Sci. Immunol."},{"key":"1151_CR54","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200218","volume":"218","author":"DH Paik","year":"2021","unstructured":"Paik, D. H. & Farber, D. L. Influenza infection fortifies local lymph nodes to promote lung-resident heterosubtypic immunity. J. Exp. Med. 218, e20200218 (2021).","journal-title":"J. Exp. Med."},{"key":"1151_CR55","doi-asserted-by":"publisher","first-page":"9217","DOI":"10.1128\/JVI.01069-10","volume":"84","author":"JR Teijaro","year":"2010","unstructured":"Teijaro, J. R., Verhoeven, D., Page, C. A., Turner, D. & Farber, D. L. Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. J. Virol. 84, 9217\u20139226 (2010).","journal-title":"J. Virol."},{"key":"1151_CR56","doi-asserted-by":"crossref","unstructured":"Zens, K. D., Chen, J. K. & Farber, D. L. Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection. JCI Insight 1, e85832 (2016).","DOI":"10.1172\/jci.insight.85832"},{"key":"1151_CR57","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.4049\/jimmunol.1102243","volume":"187","author":"JR Teijaro","year":"2011","unstructured":"Teijaro, J. R. et al. Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J. Immunol. 187, 5510\u20135514 (2011).","journal-title":"J. Immunol."},{"key":"1151_CR58","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","volume":"185","author":"A Tarke","year":"2022","unstructured":"Tarke, A. et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 185, 847\u2013859.e811 (2022).","journal-title":"Cell"},{"key":"1151_CR59","doi-asserted-by":"crossref","unstructured":"Rybkina, K. et al. SARS-CoV-2 infection and recovery in children: distinct T cell responses in MIS-C compared to COVID-19. J. Exp. Med. 220, e20221518 (2023).","DOI":"10.1084\/jem.20221518"},{"key":"1151_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl9105","volume":"6","author":"MML Poon","year":"2021","unstructured":"Poon, M. M. L. et al. SARS-CoV-2 infection generates tissue-localized immunological memory in humans. Sci. Immunol. 6, eabl9105 (2021).","journal-title":"Sci. Immunol."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01151-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01151-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01151-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T04:03:05Z","timestamp":1747454585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01151-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1151"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01151-8","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.B.-O. receives research funding NIH, The National MS Society (NMSS), the Juvenile Diabetes Research Foundation (JDRF), the Canadian Institutes of Health Research, Multiple Sclerosis Society of Canada, Multiple Sclerosis Scientific Foundation and Melissa and Paul Anderson Chair in Neuroinflammation, and has received grant support to the University of Pennsylvania from Biogen Idec, Roche\/Genentech, Merck\/EMD Serono and Novartis; has Received personal fees for advisory board participation and\/or consulting from Accure, Atara Biotherapeutics, Biogen, BMS\/Celgene\/Receptos, GlaxoSmithKline, Gossamer, Janssen\/Actelion, Medimmune, Merck\/EMD Serono, Novartis, Roche\/Genentech, Sanofi-Genzyme. R.B. is the recipient of a National Multiple Sclerosis Harry Weaver Award, and has received research support from the National Multiple Sclerosis Society, the National Institutes of Health and the Department of Defense; has received research support from Biogen, Eli Lilly, Novartis and Roche Genentech; has received personal compensation for consulting from Alexion, Amgen, EMD Serono, Sanofi Genzyme, and TG Therapeutics. D.J. has received personal compensation for advisory boards and consulting for Alexion, Horizon, Roche\/Genentech, Biogen, Merck\/EMD Serono, TG Therapeutics and has received grant support to the University of Pennsylvania from Biogen Idec, Roche\/Genentech, Merck\/EMD Serono and Novartis. J.S. has research funding support from Novartis and Roche-Genentech. Z.X. has served as a Consultant for Genentech\/Roche, and the institution of Xia has received research support from NIH, the Pittsburgh Foundation and Genentech \/Roche. P.D.J. has consulted for Puretech, Biogen, Novo Nordisk and has research sponsored by Roche, Puretech, and Biogen. S.F.W. has consulted for Novartis, TG Therapetuics, Genetech and has received research support from the NIH and investigator-initiated research funding from Biogen and Novartis. R.S.F. has consulted for Alexion, Roche\/Genentech, Horizon Therapeutics, and has investigator-initiated research funded by Novartis and Biogen. All other authors declare no financial or non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}